Table 3.
Baseline characteristics of enrolled studies
| Study | Study region | Primary cancer (major organs) | Mean age (years) | Study period | Mean follow-up (months) | Number of patients | Incidence of event (%) |
|---|---|---|---|---|---|---|---|
| Cunha et al. [6] (2012) | Canada | Multiple (kidney, breast, lung) | 57.0±18.4 | 2007 to 2011 | 7.4±9.4 | 90 (167) | 11.4 |
| Sahgal et al. [28] (2013) | USA | Multiple (kidnry, breast, lung) | 57.6±18.4 | N/D | 11.5±28.8 | 252 (410) | 13.9 |
| Sung and Chang [30] (2014) | Korea | Multiple (breast, lung, sarcoma) | 51.0±15.3 | N/D | 11.0±5.4 | 72 (72) | 36.1 |
| Thibault et al. [32] (2014) | Canada | Renal cell cancer | 63.0±12.5 | October 2007 to August 2012 | 12.3±13.8 | 37 (61) | 16.4 |
| Thibault et al. [33] (2015) | USA, Canada | Renal cell cancer | 60.2±13.9 | N/D | 8.0±19.4 | 116 (187) | 18.2 |
| Lam et al. [15] (2015) | USA | Multiple (breast, prostate, lung) | 62 | January 2008 to Decmeber 2013 | N/D | 299 | 17.1 |
| Aiba et al. [1] (2016) | Japan | NSCLC | 67 | 2009 to 2013 | 10.2±13.7 | 47 | 31.9 |
| Lee et al. [20] (2016) | USA | Multiple (kidney, breast, thyroid) | 57.2±14.5 | March 2004 to March 2011 | 29.2 | 79 | 40.5 |
| Germano et al. [12] (2016) | USA | Multiple (liver, breast, lung) | 62.0±11.0 | November 2007 to January 2014 | 16.0±18.0 | 79 (143) | 21.0 |
| Virk et al. [37] (2017) | USA | Multiple (renal, prostate, sarcoma) | 60.7±4.6 | 2005 to 2013 | 12.6±7.2 | 323 | 8.0 |
| Bollen et al. [3] (2017) | Netherland | Multiple (lung, breast, kidney) | 60.4±13.8 | January 2000 to December 2010 | N/D | 110 | 14.5 |
| Shi et al. [29] (2018) | USA | Multiple (breast, lung) | 60.0±18.9 | 2006 to 2013 | 5.9 | 203 (250) | 20.4 |
| Lee et al. [19] (2018) | Korea | Colorectal cancer | 61.0±10.7 | January 2007 to December 2014 | 10.0±24.5 | 53 (147) | 15.0 |
| Chang et al. [5] (2018) | Korea | Multiple (breast, lung, liver) | 55.0±13.0 | January 2008 to December 2009 | 24 | 78 | 26.9 |
| Fourney et al. [10] (2011) | World | N/D | N/D | N/D | N/D | 30 | N/D |
| Teixeira et al. [31] (2013) | Brazil | N/D | N/D | N/D | N/D | 40 | N/D |
| Campos et al. [4] (2014) | N/D | Multiple (kidney, breast, lung) | 65.0±14.3 | January 2004 to March 2011 | N/D | 30 | N/D |
| Fisher et al. [9] (2014) | World | Multiple (lung, prostate, breast) | N/D | N/D | N/D | 30 | N/D |
| Fisher et al. [8] (2014) | World | Multiple (lung, prostate, breast) | N/D | N/D | N/D | 30 | N/D |
| Arana et al. [2] (2016) | Spain | Multiple (breast, prostate, lung) | N/D | N/D | N/D | 90 | N/D |
| Fox et al. [11] (2017) | Canada | N/D | N/D | N/D | N/D | 30 | N/D |
Values are presented as mean±standard deviation or number (segments). N/D : not described, NSCLC : non-small cell lung cancer